The Egyptian Journal of Internal Medicine

SEP 29, 2026 · JOURNAL ARTICLE

C-peptide in MASLD – a potential driver of hepatic steatosis and fibrosis

The Egyptian Journal of Internal Medicine

Abstract Metabolically-dysfunction-associated steatotic liver disease (MASLD), the leading chronic liver condition worldwide, is driven by hyperinsulinemia and insulin resistance,

SEP 11, 2026 · JOURNAL ARTICLE

Single Point Insulin Sensitivity Estimator (SPISE), a novel score to evaluate insulin sensitivity, is predictive in anthropometry specified adults with type 2 diabetes mellitus

The Egyptian Journal of Internal Medicine

Abstract Purpose The study was aimed at the assessment of non-insulin-based markers as alternatives to the conventional insulin-based indices in anthropometry specified type 2 Diab

SEP 9, 2026 · JOURNAL ARTICLE

Continuous biosensing and real-time metabolic monitoring in obesity, diabetes, and diabetic kidney disease: implications for precision diabetes and kidney care

The Egyptian Journal of Internal Medicine

A narrative review synthesizing established and emerging biosensor technologies for diabetes and kidney disease monitoring, offering expert perspective on clinical applications and implementation barriers rather than reporting original research evidence.

AUG 18, 2026 · JOURNAL ARTICLE

Evaluation of sirtuin 1 serum level and gene expression in patients with metabolic syndrome accompanied by metabolic dysfunction-associated steatotic liver disease

The Egyptian Journal of Internal Medicine

Small uncontrolled case-control study (n=17 per group) examining biomarker associations and diagnostic accuracy in a cross-sectional design; suggestive of SIRT1's potential as a marker but lacks prospective validation, treatment outcome data, and external replication.

AUG 6, 2026 · JOURNAL ARTICLE

Ebola virus disease at the human–animal–environment interface: a scoping review of recent outbreaks, transmission dynamics, and future preventive strategies

The Egyptian Journal of Internal Medicine

A scoping review synthesizing recent outbreak reports and evidence through May 2026, descriptive in nature with no comparative efficacy analysis, presenting epidemiological patterns and therapeutic comparisons without formal meta-analysis or controlled design.